A77 1726
DHODH inhibitor / A pyrimidine biosynthesis inhibitor and immunomodulator.1 Inhibits the mitochondrial dihydroorotate dehydrogenase (DHODH).2 Leflunomide is rapidly metabolized in human hepatocytes to A77 1726.3 Cell permeable.
Biochemicals & reagents
108605-62-5
Teriflunomide
1) Manna et al. (1999), Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression; J. Immunol., 162 2095 2) Davis et al. (1996), The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase; Biochemistry, 35 1270 3) Seah et al. (2008), Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726; Drug Metab. Lett., 2 153
-20°C
TARGET: Dehydrogenase (GAPDH, GPDH, IMPDH, PHGDH, LDH, DHODH, ALDH, GDH, IDH, UGDH, DPD, DHPDH, KGDH, PDH, and MDH) -- PATHWAY: Nucleoside/tide biosynthesis; Transcription; NFkappaB; DNA synthesis -- RESEARCH AREA: Immunology -- DISEASE AREA: Inflammation; Infectious disease